Objective: To observe the clinical outcomes on usage of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in type 2 diabetic nephropathy patients.Methods: A total 70 patients diagnosed with diabetic nephropathy were treated with ACEIs or ARBs were enrolled in this study. The data was collected from the out patients and the physician. A data collection form was used for collecting patient data. The form was used to record the details of patient's demographics, history of diabetes mellitus, duration of diabetes mellitus co morbidities, food habits and laboratory parameters such as serum creatinine, HbA1c and all the relevant things. The study has obtained ethical clearance from the institution ethics co...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitor...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background: Beneficial effect in reducing microalbuminuria of diabetic nephropathy with angiotensin ...
When used to delay the progression of early nephropathy in patients with type 2 diabetes mellitus, a...
This review assesses the protective effect of ACEIs and ARBs on microalbuminuria in diabetic patient...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Background: There is, to our knowledge, no study that has directly compared angiotensin-converting e...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitor...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background and objective: Incidence and prevalence of Diabetes in developing countries like India is...
Background: Beneficial effect in reducing microalbuminuria of diabetic nephropathy with angiotensin ...
When used to delay the progression of early nephropathy in patients with type 2 diabetes mellitus, a...
This review assesses the protective effect of ACEIs and ARBs on microalbuminuria in diabetic patient...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Background: There is, to our knowledge, no study that has directly compared angiotensin-converting e...
Aim: To compare effectiveness of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin recept...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Background: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists ...
Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitor...